SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3

SP142 programmed cell death ligand 1 (PD-L1) status predicts response to atezolizumab in triple-negative breast carcinoma (TNBC). Prevalence of VENTANA PD-L1 (SP142) Assay positivity, concordance with the VENTANA PD-L1 (SP263) Assay and Dako PD-L1 IHC 22C3 pharmDx assay, and association with clinico...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Jia-Min B., Castles, Belinda, Byrne, David J., Button, Peter, Hendry, Shona, Lakhani, Sunil R., Sivasubramaniam, Vanathi, Cooper, Wendy A., Armes, Jane, Millar, Ewan K.A., Raymond, Wendy, Roberts-Thomson, Samuel, Kumar, Beena, Burr, Marian, Selinger, Christina, Harvey, Kate, Chan, Charles, Beith, Jane, Clouston, David, O’Toole, Sandra A., Fox, Stephen B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277187/
https://www.ncbi.nlm.nih.gov/pubmed/34232604
http://dx.doi.org/10.1097/PAS.0000000000001701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277187/
https://www.ncbi.nlm.nih.gov/pubmed/34232604
http://dx.doi.org/10.1097/PAS.0000000000001701

Ejemplares similares